Tempest Therapeutics (TPST) said Monday the US Food and Drug Administration granted fast track designation to amezalpat for the potential treatment of hepatocellular carcinoma, a type of liver cancer.
The company said the designation allows for increased communication with the FDA and potential eligibility for accelerated approval and priority review. The designation follows an orphan drug designation in January, Tempest added.
Tempest said amezalpat is being evaluated in combination with atezolizumab and bevacizumab in a global phase 1b/2 trial for first-line treatment of unresectable or metastatic hepatocellular carcinoma.
Shares of the company were up 1.8% in recent Monday trading.
Price: 0.89, Change: +0.02, Percent Change: +1.77
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。